Latest Plexxikon Stories
Lead Compound, Quizartinib, Will Further Build Daiichi Sankyo Oncology Pipeline TOKYO and SAN DIEGO, Sept. 28, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Ltd.
SAN DIEGO, Aug. 12, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that K.
Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf®) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer.
Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.
PARSIPPANY, N.J., Aug.
PARSIPPANY, N.J. and TOKYO, May 11, 2011 /PRNewswire/ -- Daiichi Sankyo announced that applications have been submitted for market approval for vemurafenib (PLX4032/RG7204) for the treatment of metastatic melanoma to the U.S.
A breakthrough discovery may offer an effective new treatment for melanoma, one of the deadliest forms of skin cancer, scientists said on Wednesday.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.